Pfizer Loses Marketing Exclusivity For Diflucan

Law360, New York (July 29, 2004, 12:00 AM EDT) -- The U.S. Food and Drug Administration has approved marketing applications from several generic drug makers to begin selling generic versions of Pfizer Inc.'s yeast infection treatment Diflucan.

Drug companies Mylan Laboratories Inc., Ivax Corp., Par Pharmaceutical Cos., and Taro Pharmaceutical Industries Ltd. said the FDA approved abbreviated new drug applications for them to market 50 mg, 100 mg, 150 mg and 200 mg tablets of the product.

Israel-based Teva Pharmaceutical Industries Ltd. said it received approval for the same tablet doses along with approval to market...
To view the full article, register now.